Identification of a JAK2 mutation in polycythemia vera
View Patent ↗The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
1. A method, comprising:
a) obtaining and analyzing a nucleic acid sample from a human patient having erythrocytosis, wherein the human patient having erythrocytosis has a hematocrit level of higher than 51%, wherein the analyzing comprises:
a1) sequencing a region of the nucleic acid sample comprising position 2343 of SEQ ID NO: 2, or
a2) hybridizing the nucleic acid sample with at least one probe comprising at least 10 consecutive nucleotides of SEQ ID NO: 2 comprising position 2343 of SEQ ID NO: 2
b) detecting the presence or absence of a thymine (T) in the JAK2 gene at position 2343 of SEQ ID NO: 2 in the nucleic acid sample;
c) T is present at position 2343, treating the patient for polycythemia vera (PV) without quantifying red cell mass, quantifying erythroid endogenous colonies or testing bone marrow of the patient; and
d) if T is absent at position 2343 of SEQ ID NO 2 without quantifying red cell mass, quantifying erythroid endogenous colonies or testing bone marrow of the patient.
2. The method of claim 1 , wherein the at least one probe is labeled with at least one marker and detecting comprises detection of the signal produced by the at least one probe.
3. The method of claim 1 , wherein the hybridizing comprises hybridizing with at least two probes.